Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function

Cell Cycle

Volumn 13, Issue 17, 2014, Pages 2790-2797

  Szalontay, Luca ^a   Schally, Andrew V ^a,b,c   Popovics, Petra ^a,b,e   Vidaurre, Irving ^a   Krishan, Awtar ^b   Zarandi, Marta ^a,b   Cai, Ren Zhi ^a,b   Klukovits, Anna ^a,b   Block, Norman L ^a,b   Rick, Ferenc G ^a,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Growth hormone releasing hormone antagonist; Melanoma; P27; Targeted therapy; Xenografted mouse model

Indexed keywords

ANTINEOPLASTIC AGENT; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; MIA 602; MIA 606; MIA 690; PROTEIN P27; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GHRH(1-29)NH2, (PHAC-ADA)(0)-TYR(1), ARG(2), FPA(5,6), ALA(8), HAR(9), TYR(ME)(10), HIS(11), ORN(12,) ABU(15), HIS(20), ORN(21), NLE(27), ARG(28), HAR(29)-; GROWTH HORMONE RELEASING FACTOR; HORMONE RECEPTOR; NEUROPEPTIDE RECEPTOR; SERMORELIN; SOMATOTROPIN RELEASING HORMONE RECEPTOR;

A375 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL LINE; MOUSE; NONHUMAN; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH HORMONE-RELEASING HORMONE; HUMANS; MELANOMA; MICE, NUDE; RECEPTORS, NEUROPEPTIDE; RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE; SERMORELIN; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907438662     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2015.945879     Document Type: Article

References (47)

1. Slipicevic A, Herlyn M. Narrowing the knowledge gaps for melanoma. Upsala J Med Sci 2012; 117:237-43; PMID:22339359; http://dx.doi.org/10.3109/03009734.2012.658977
2. Usher-Smith JA, Emery J, Kassianos AP, Walter FM. Risk Prediction Models for Melanoma: A Systematic Review. Cancer Epidemiol Biomarkers Prev 2014; 23:1450-63; PMID:24895414; http://dx.doi.org/10.1158/1055-9965.EPI-14-0295
3. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351:998-1012; PMID:15342808; http://dx.doi.org/10.1056/NEJMra041245
4. Lee B, Mukhi N, Liu D. Current management and novel agents for malignant melanoma. J Hematol Oncol 2012; 5:3; PMID:22333219; http://dx.doi.org/10.1186/1756-8722-5-3
5. Schally AV, Varga JL, Engel JB. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 2008; 4:33-43; PMID:18084344; http://dx.doi.org/10.1038/ncpendmet0677
6. Rick FG, Schally AV, Szalontay L, Block NL, Szepeshazi K, Nadji M, Zarandi M, Hohla F, Buchholz S, Seitz S. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proc Natl Acad Sci USA 2012; 109: 1655-60; PMID:22307626; http://dx.doi.org/10.1073/pnas.1120588109
7. Cai R, Schally AV, Cui T, Szalontay L, Halmos G, Sha W, Kovacs M, Jaszberenyi M, He J, Rick FG, et al. Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities. Peptides 2014; 52:104-12; PMID:24373935; http://dx.doi.org/10.1016/j.peptides.2013.12.010
8. Fahrenholtz CD, Rick FG, Garcia MI, Zarandi M, Cai RZ, Block NL, Schally AV, Burnstein KL. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer. Proc Natl Acad Sci USA 2014; 111:1084-9; PMID:24395797; http://dx.doi.org/10.1073/pnas.1323102111
9. Kiaris H, Chatzistamou I, Papavassiliou AG, Schally AV. Growth hormone-releasing hormone: not only a neurohormone. Trends Endocrinol Metab 2011; 22:311-7; PMID:21530304; http://dx.doi.org/10.1016/j.tem.2011.03.006
10. Rick FG, Saadat SH, Szalontay L, Block NL, Kazzazi A, Djavan B, Schally AV. Hormonal manipulation of benign prostatic hyperplasia. Curr Opin Urol 2013; 23:17-24; PMID:23202285; http://dx.doi.org/10.1097/MOU.0b013e32835abd18
11. Rick FG, Schally AV, Block NL, Abi-Chaker A, Krishan A, Szalontay L. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormonereleasing hormone in shrinking experimental benign prostatic hyperplasia. Prostate 2013; 73:873-83; PMID:23280565; http://dx.doi.org/10.1002/pros.22633
12. Rick FG, Szalontay L, Schally AV, Block NL, Nadji M, Szepeshazi K, Vidaurre I, Zarandi M, Kovacs M, Rekasi Z. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. J Urol 2012; 187:1498-504; PMID:22341819; http://dx.doi.org/10.1016/j.juro.2011.11.081
13. Jaszberenyi M, Rick FG, Szalontay L, Block NL, Zarandi M, Cai RZ, Schally AV. Beneficial effects of novel antagonists of GHRH in different models of Alzheimer's disease. Aging 2012; 4:755-67;PMID:23211425
14. Kanashiro-Takeuchi RM, Takeuchi LM, Rick FG, Dulce R, Treuer AV, Florea V, Rodrigues CO, Paulino EC, Hatzistergos KE, Selem SM, et al. Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI). Proc Natl Acad Sci USA 2012; 109:559-63; PMID:22203988; http://dx.doi.org/10.1073/pnas.1119203109
15. Lucas R, Sridhar S, Rick FG, Gorshkov B, Umapathy NS, Yang G, Oseghale A, Verin AD, Chakraborty T, Matthay MA, et al. Agonist of growth hormonereleasing hormone reduces pneumolysin-induced pulmonary permeability edema. Proc Natl Acad Sci U S A 2012; 109:2084-9; PMID:22308467; http://dx.doi.org/10.1073/pnas.1121075109
16. Lucas R, Czikora I, Sridhar S, Zemskov E, Gorshkov B, Siddaramappa U, Oseghale A, Lawson J, Verin A, Rick FG, et al. Mini-review: novel therapeutic strategies to blunt actions of pneumolysin in the lungs. Toxins 2013; 5:1244-60; PMID:23860351; http://dx.doi.org/10.3390/toxins5071244
17. LeRoith D, Roberts CT, Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195:127-37; PMID:12767520; http://dx.doi.org/10.1016/S0304-3835(03)00159-9
18. Schally AV. New approaches to the therapy of various tumors based on peptide analogues. HormMetab Res 2008; 40:315-22; PMID:18491250; http://dx.doi. org/10.1055/s-2008-1073142
19. Havt A, Schally AV, Halmos G, Varga JL, Toller GL, Horvath JE, Szepeshazi K, Koster F, Kovitz K, Groot K, et al. The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci USA 2005;102:17424-9; PMID:16299104; http://dx.doi.org/10.1073/pnas.0506844102
20. Pozsgai E, Schally AV, Hocsak E, Zarandi M, Rick F, Bellyei S. The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines. Int J Oncol 2011; 39:1025-32; PMID:21701777; http://dx.doi.org/10.3892/ijo.2011.1098
21. Hohla F, Buchholz S, Schally AV, Seitz S, Rick FG, Szalontay L, Varga JL, Zarandi M, Halmos G, Vidaurre I, et al. GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle 2009; 8:3149-56; PMID:19755849; http://dx.doi.org/10.4161/cc.8.19.9698
22. Chatzistamou I, Volakaki AA, Schally AV, Kiaris H, Kittas C. Expression of growth hormonereleasing hormone receptor splice variant 1 in primary human melanomas. Regul Peptides 2008; 147:33-6; PMID:18255167; http://dx.doi.org/10.1016/j.regpep.2007.12.008
23. Jaszberenyi M, Schally AV, Block NL, Zarandi M, Cai RZ, Vidaurre I, Szalontay L, Jayakumar AR, Rick FG. Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro. Targeted Oncol 2013; 8:281-90; PMID:23371031; http://dx.doi.org/10.1007/s11523-013-0264-y
24. Papadia A, Schally AV, Halmos G, Varga JL, Seitz S, Buchholz S, Rick F, Zarandi M, Bellyei S, Treszl A, et al. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer. Horm Metab Res 2011; 43:816-20; PMID:22009378; http://dx.doi.org/10.1055/s-0031-1287766
25. Perez R, Schally AV, Vidaurre I, Rincon R, Block NL, Rick FG. Antagonists of growth hormonereleasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers. Oncotarget 2012; 3:988-97; PMID:22941871
26. Rick FG, Seitz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Buchholz S, Block NL, Hohla F. GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer. Cell Cycle 2012; 11:4203-10; PMID:23095641; http://dx.doi.org/10.4161/cc.22498
27. Seitz S, Rick FG, Schally AV, Treszl A, Hohla F, Szalontay L, Zarandi M, Ortmann O, Engel JB, Buchholz S. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers. Oncol Rep 2013; 30:413-8; PMID:23624870
28. Stangelberger A, Schally AV, Rick FG, Varga JL, Baker B, Zarandi M, Halmos G. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins. Prostate 2012; 72:555-65; PMID:21796649; http://dx.doi.org/10.1002/pros.21458
29. Kovacs M, Schally AV, Hohla F, Rick FG, Pozsgai E, Szalontay L, Varga JL, Zarandi M. A correlation of endocrine and anticancer effects of some antagonists of GHRH. Peptides 2010; 31:1839-46; PMID:20633588; http://dx.doi.org/10.1016/j. peptides.2010.07.006
30. Abdel-Wahab M, Schally AV, Rick FG, Szalontay L, Block NL, Jorda M, Mahmoud O, Markoe A, Shi YF, Reiner T, et al. Antagonists of growth hormone releasing hormone (GHRH) given before whole body radiation lead to modulation of radiation response and organ-specific changes in the expression of angiogenesis. J Radiat Oncol 2012; 1:389-96; http://dx.doi.org/10.1007/s13566-012-0031-1
31. Rick FG, Schally AV, Block NL, Nadji M, Szepeshazi K, Zarandi M, Vidaurre I, Perez R, Halmos G, Szalontay L. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci U S A 2011; 108:3755-60; PMID:21321192; http://dx.doi.org/10.1073/pnas.1018086108
32. Klukovits A, Schally AV, Szalontay L, Vidaurre I, Papadia A, Zarandi M, Varga JL, Block NL, Halmos G. Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers. Cancer 2012; 118:670-80; PMID:21751186; http://dx.doi.org/10.1002/cncr.26291
33. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000; 183:10-7; PMID:10699961; http://dx.doi.org/10.1002/(SICI)1097-4652(200004) 183:13.0.CO;2-I
34. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8:253-67; PMID:18354415; http://dx.doi.org/10.1038/nrc2347
35. Chen G, Cheng Y, Zhang Z, Martinka M, Li G. Prognostic significance of cytoplasmic p27 expression in human melanoma. Cancer Epidemiol Biomar Prev: A Pub Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 2011; 20:2212-21; http://dx.doi.org/10.1158/1055-9965.EPI-11-0472
36. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6: 729-34; PMID:16915295; http://dx.doi.org/10.1038/nrc1974
37. Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, Slingerland JM. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell 2008; 30:701-11; PMID:18570873; http://dx.doi.org/10.1016/j.molcel.2008.04.027
38. Siejka A, Barabutis N, Schally AV. GHRH antagonist MZ-5-156 increases the expression of AMPK in A549 lung cancer cells. Cell Cycle 2011; 10:3714-8; PMID:22041656; http://dx.doi.org/10.4161/cc.10.21.17904
39. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4:E131-6; PMID:11988758; http://dx.doi.org/10.1038/ncb0502-e131
40. Rutberg SE, Goldstein IM, Yang YM, Stackpole CW, Ronai Z. Expression and transcriptional activity of AP-1, CRE, and URE binding proteins in B16 mouse melanoma subclones. Mol Carcin 1994; 10:82-7; PMID:8031468; http://dx.doi.org/10.1002/mc.2940100205
41. Scheibenbogen C, Mohler T, Haefele J, Hunstein W, Keilholz U. Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Res 1995; 5:179-81; PMID:7640519; http://dx.doi.org/10.1097/00008390-199506000-00006
42. Brennecke S, Deichmann M, Naeher H, Kurzen H. Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res 2005; 15:515-22; PMID:16314737; http://dx.doi.org/10.1097/00008390-200512000-00006
43. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6(Suppl 1):S11-4; PMID:10685652
44. Sacca R, Cuff CA, Lesslauer W, Ruddle NH. Differential activities of secreted lymphotoxin-alpha3 and membrane lymphotoxin-alpha1beta2 in lymphotoxin-induced inflammation: critical role of TNF receptor 1 signaling. J Immunol 1998; 160:485-91
45. Cuff CA, Schwartz J, Bergman CM, Russell KS, Bender JR, Ruddle NH. Lymphotoxin alpha3 induces chemokines and adhesion molecules: insight into the role of LT alpha in inflammation and lymphoid organ development. J Immunol 1998; 161:6853-60; PMID:9862717
46. Schrama D, thor Straten P, Fischer WH, McLellan AD, Brocker EB, Reisfeld RA, Becker JC. Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 2001; 14:111-21; PMID:11239444; http://dx.doi.org/10.1016/S1074-7613(01)00094-2
47. Zarandi M, Horvath JE, Halmos G, Pinski J, Nagy A, Groot K, Rekasi Z, Schally AV. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci U S A 1994; 91:12298-302; PMID:7991622; http://dx.doi.org/10.1073/pnas.91.25.12298